Research ArticleArticle
Open Access
Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study
John D. Reveille, Atul Deodhar, Paul H. Caldron, Anna Dudek, Diane D. Harrison, Lilianne Kim, Kim Hung Lo, Jocelyn H. Leu and Elizabeth C. Hsia
The Journal of Rheumatology March 2019, jrheum.180718; DOI: https://doi.org/10.3899/jrheum.180718
John D. Reveille
From the University of Texas McGovern Medical School, Houston, Texas; Oregon Health & Science University, Portland, Oregon; Arizona Arthritis and Rheumatology Associates, Phoenix, Arizona; Janssen Research & Development LLC, Spring House, Pennsylvania; University of Pennsylvania, Philadelphia, Pennsylvania, USA; AMED Medical Center, Warsaw, Poland. This study was funded by Janssen Research & Development LLC, which manufactures golimumab. Drs. Caldron and Dudek served as trial investigators for Janssen. Dr. Reveille has received consultancies from Eli Lilly, Janssen, Novartis, Pfizer, and UCB, has served as a trial investigator for Janssen and Eli Lilly, and has received a research grant from Janssen. Dr. Deodhar has received consultancies, speaking fees, and/or honoraria from Eli Lilly, Janssen, Novartis, Pfizer, and UCB. Drs. Harrison and Hsia, and L. Kim, K.H. Lo, and J.H. Leu are or were employees of Janssen Research & Development LLC at the time this work was performed, and own stock in Johnson & Johnson, of which Janssen Research & Development LLC is a wholly owned subsidiary. J.D. Reveille, MD, University of Texas McGovern Medical School; A. Deodhar, MD, Oregon Health & Science University; P.H. Caldron, DO, Arizona Arthritis and Rheumatology Associates; A. Dudek, MD, PhD, AMED Medical Center; D.D. Harrison, MD, MPH, Janssen Research & Development LLC; L. Kim, PhD, Janssen Research & Development LLC; K.H. Lo, PhD, Janssen Research & Development LLC; J.H. Leu, PharmD, PhD, Janssen Research & Development LLC; E.C. Hsia, MD, MSCE, Janssen Research & Development LLC, and University of Pennsylvania. Address correspondence to Dr. E.C. Hsia, Janssen Research & Development LLC, 1400 McKean Road, PO Box 776, Spring House, Pennsylvania 19477, USA. E-mail: ehsia@its.jnj.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication November 22, 2018.
Atul Deodhar
From the University of Texas McGovern Medical School, Houston, Texas; Oregon Health & Science University, Portland, Oregon; Arizona Arthritis and Rheumatology Associates, Phoenix, Arizona; Janssen Research & Development LLC, Spring House, Pennsylvania; University of Pennsylvania, Philadelphia, Pennsylvania, USA; AMED Medical Center, Warsaw, Poland. This study was funded by Janssen Research & Development LLC, which manufactures golimumab. Drs. Caldron and Dudek served as trial investigators for Janssen. Dr. Reveille has received consultancies from Eli Lilly, Janssen, Novartis, Pfizer, and UCB, has served as a trial investigator for Janssen and Eli Lilly, and has received a research grant from Janssen. Dr. Deodhar has received consultancies, speaking fees, and/or honoraria from Eli Lilly, Janssen, Novartis, Pfizer, and UCB. Drs. Harrison and Hsia, and L. Kim, K.H. Lo, and J.H. Leu are or were employees of Janssen Research & Development LLC at the time this work was performed, and own stock in Johnson & Johnson, of which Janssen Research & Development LLC is a wholly owned subsidiary. J.D. Reveille, MD, University of Texas McGovern Medical School; A. Deodhar, MD, Oregon Health & Science University; P.H. Caldron, DO, Arizona Arthritis and Rheumatology Associates; A. Dudek, MD, PhD, AMED Medical Center; D.D. Harrison, MD, MPH, Janssen Research & Development LLC; L. Kim, PhD, Janssen Research & Development LLC; K.H. Lo, PhD, Janssen Research & Development LLC; J.H. Leu, PharmD, PhD, Janssen Research & Development LLC; E.C. Hsia, MD, MSCE, Janssen Research & Development LLC, and University of Pennsylvania. Address correspondence to Dr. E.C. Hsia, Janssen Research & Development LLC, 1400 McKean Road, PO Box 776, Spring House, Pennsylvania 19477, USA. E-mail: ehsia@its.jnj.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication November 22, 2018.
Paul H. Caldron
From the University of Texas McGovern Medical School, Houston, Texas; Oregon Health & Science University, Portland, Oregon; Arizona Arthritis and Rheumatology Associates, Phoenix, Arizona; Janssen Research & Development LLC, Spring House, Pennsylvania; University of Pennsylvania, Philadelphia, Pennsylvania, USA; AMED Medical Center, Warsaw, Poland. This study was funded by Janssen Research & Development LLC, which manufactures golimumab. Drs. Caldron and Dudek served as trial investigators for Janssen. Dr. Reveille has received consultancies from Eli Lilly, Janssen, Novartis, Pfizer, and UCB, has served as a trial investigator for Janssen and Eli Lilly, and has received a research grant from Janssen. Dr. Deodhar has received consultancies, speaking fees, and/or honoraria from Eli Lilly, Janssen, Novartis, Pfizer, and UCB. Drs. Harrison and Hsia, and L. Kim, K.H. Lo, and J.H. Leu are or were employees of Janssen Research & Development LLC at the time this work was performed, and own stock in Johnson & Johnson, of which Janssen Research & Development LLC is a wholly owned subsidiary. J.D. Reveille, MD, University of Texas McGovern Medical School; A. Deodhar, MD, Oregon Health & Science University; P.H. Caldron, DO, Arizona Arthritis and Rheumatology Associates; A. Dudek, MD, PhD, AMED Medical Center; D.D. Harrison, MD, MPH, Janssen Research & Development LLC; L. Kim, PhD, Janssen Research & Development LLC; K.H. Lo, PhD, Janssen Research & Development LLC; J.H. Leu, PharmD, PhD, Janssen Research & Development LLC; E.C. Hsia, MD, MSCE, Janssen Research & Development LLC, and University of Pennsylvania. Address correspondence to Dr. E.C. Hsia, Janssen Research & Development LLC, 1400 McKean Road, PO Box 776, Spring House, Pennsylvania 19477, USA. E-mail: ehsia@its.jnj.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication November 22, 2018.
Anna Dudek
From the University of Texas McGovern Medical School, Houston, Texas; Oregon Health & Science University, Portland, Oregon; Arizona Arthritis and Rheumatology Associates, Phoenix, Arizona; Janssen Research & Development LLC, Spring House, Pennsylvania; University of Pennsylvania, Philadelphia, Pennsylvania, USA; AMED Medical Center, Warsaw, Poland. This study was funded by Janssen Research & Development LLC, which manufactures golimumab. Drs. Caldron and Dudek served as trial investigators for Janssen. Dr. Reveille has received consultancies from Eli Lilly, Janssen, Novartis, Pfizer, and UCB, has served as a trial investigator for Janssen and Eli Lilly, and has received a research grant from Janssen. Dr. Deodhar has received consultancies, speaking fees, and/or honoraria from Eli Lilly, Janssen, Novartis, Pfizer, and UCB. Drs. Harrison and Hsia, and L. Kim, K.H. Lo, and J.H. Leu are or were employees of Janssen Research & Development LLC at the time this work was performed, and own stock in Johnson & Johnson, of which Janssen Research & Development LLC is a wholly owned subsidiary. J.D. Reveille, MD, University of Texas McGovern Medical School; A. Deodhar, MD, Oregon Health & Science University; P.H. Caldron, DO, Arizona Arthritis and Rheumatology Associates; A. Dudek, MD, PhD, AMED Medical Center; D.D. Harrison, MD, MPH, Janssen Research & Development LLC; L. Kim, PhD, Janssen Research & Development LLC; K.H. Lo, PhD, Janssen Research & Development LLC; J.H. Leu, PharmD, PhD, Janssen Research & Development LLC; E.C. Hsia, MD, MSCE, Janssen Research & Development LLC, and University of Pennsylvania. Address correspondence to Dr. E.C. Hsia, Janssen Research & Development LLC, 1400 McKean Road, PO Box 776, Spring House, Pennsylvania 19477, USA. E-mail: ehsia@its.jnj.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication November 22, 2018.
Diane D. Harrison
From the University of Texas McGovern Medical School, Houston, Texas; Oregon Health & Science University, Portland, Oregon; Arizona Arthritis and Rheumatology Associates, Phoenix, Arizona; Janssen Research & Development LLC, Spring House, Pennsylvania; University of Pennsylvania, Philadelphia, Pennsylvania, USA; AMED Medical Center, Warsaw, Poland. This study was funded by Janssen Research & Development LLC, which manufactures golimumab. Drs. Caldron and Dudek served as trial investigators for Janssen. Dr. Reveille has received consultancies from Eli Lilly, Janssen, Novartis, Pfizer, and UCB, has served as a trial investigator for Janssen and Eli Lilly, and has received a research grant from Janssen. Dr. Deodhar has received consultancies, speaking fees, and/or honoraria from Eli Lilly, Janssen, Novartis, Pfizer, and UCB. Drs. Harrison and Hsia, and L. Kim, K.H. Lo, and J.H. Leu are or were employees of Janssen Research & Development LLC at the time this work was performed, and own stock in Johnson & Johnson, of which Janssen Research & Development LLC is a wholly owned subsidiary. J.D. Reveille, MD, University of Texas McGovern Medical School; A. Deodhar, MD, Oregon Health & Science University; P.H. Caldron, DO, Arizona Arthritis and Rheumatology Associates; A. Dudek, MD, PhD, AMED Medical Center; D.D. Harrison, MD, MPH, Janssen Research & Development LLC; L. Kim, PhD, Janssen Research & Development LLC; K.H. Lo, PhD, Janssen Research & Development LLC; J.H. Leu, PharmD, PhD, Janssen Research & Development LLC; E.C. Hsia, MD, MSCE, Janssen Research & Development LLC, and University of Pennsylvania. Address correspondence to Dr. E.C. Hsia, Janssen Research & Development LLC, 1400 McKean Road, PO Box 776, Spring House, Pennsylvania 19477, USA. E-mail: ehsia@its.jnj.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication November 22, 2018.
Lilianne Kim
From the University of Texas McGovern Medical School, Houston, Texas; Oregon Health & Science University, Portland, Oregon; Arizona Arthritis and Rheumatology Associates, Phoenix, Arizona; Janssen Research & Development LLC, Spring House, Pennsylvania; University of Pennsylvania, Philadelphia, Pennsylvania, USA; AMED Medical Center, Warsaw, Poland. This study was funded by Janssen Research & Development LLC, which manufactures golimumab. Drs. Caldron and Dudek served as trial investigators for Janssen. Dr. Reveille has received consultancies from Eli Lilly, Janssen, Novartis, Pfizer, and UCB, has served as a trial investigator for Janssen and Eli Lilly, and has received a research grant from Janssen. Dr. Deodhar has received consultancies, speaking fees, and/or honoraria from Eli Lilly, Janssen, Novartis, Pfizer, and UCB. Drs. Harrison and Hsia, and L. Kim, K.H. Lo, and J.H. Leu are or were employees of Janssen Research & Development LLC at the time this work was performed, and own stock in Johnson & Johnson, of which Janssen Research & Development LLC is a wholly owned subsidiary. J.D. Reveille, MD, University of Texas McGovern Medical School; A. Deodhar, MD, Oregon Health & Science University; P.H. Caldron, DO, Arizona Arthritis and Rheumatology Associates; A. Dudek, MD, PhD, AMED Medical Center; D.D. Harrison, MD, MPH, Janssen Research & Development LLC; L. Kim, PhD, Janssen Research & Development LLC; K.H. Lo, PhD, Janssen Research & Development LLC; J.H. Leu, PharmD, PhD, Janssen Research & Development LLC; E.C. Hsia, MD, MSCE, Janssen Research & Development LLC, and University of Pennsylvania. Address correspondence to Dr. E.C. Hsia, Janssen Research & Development LLC, 1400 McKean Road, PO Box 776, Spring House, Pennsylvania 19477, USA. E-mail: ehsia@its.jnj.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication November 22, 2018.
Kim Hung Lo
From the University of Texas McGovern Medical School, Houston, Texas; Oregon Health & Science University, Portland, Oregon; Arizona Arthritis and Rheumatology Associates, Phoenix, Arizona; Janssen Research & Development LLC, Spring House, Pennsylvania; University of Pennsylvania, Philadelphia, Pennsylvania, USA; AMED Medical Center, Warsaw, Poland. This study was funded by Janssen Research & Development LLC, which manufactures golimumab. Drs. Caldron and Dudek served as trial investigators for Janssen. Dr. Reveille has received consultancies from Eli Lilly, Janssen, Novartis, Pfizer, and UCB, has served as a trial investigator for Janssen and Eli Lilly, and has received a research grant from Janssen. Dr. Deodhar has received consultancies, speaking fees, and/or honoraria from Eli Lilly, Janssen, Novartis, Pfizer, and UCB. Drs. Harrison and Hsia, and L. Kim, K.H. Lo, and J.H. Leu are or were employees of Janssen Research & Development LLC at the time this work was performed, and own stock in Johnson & Johnson, of which Janssen Research & Development LLC is a wholly owned subsidiary. J.D. Reveille, MD, University of Texas McGovern Medical School; A. Deodhar, MD, Oregon Health & Science University; P.H. Caldron, DO, Arizona Arthritis and Rheumatology Associates; A. Dudek, MD, PhD, AMED Medical Center; D.D. Harrison, MD, MPH, Janssen Research & Development LLC; L. Kim, PhD, Janssen Research & Development LLC; K.H. Lo, PhD, Janssen Research & Development LLC; J.H. Leu, PharmD, PhD, Janssen Research & Development LLC; E.C. Hsia, MD, MSCE, Janssen Research & Development LLC, and University of Pennsylvania. Address correspondence to Dr. E.C. Hsia, Janssen Research & Development LLC, 1400 McKean Road, PO Box 776, Spring House, Pennsylvania 19477, USA. E-mail: ehsia@its.jnj.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication November 22, 2018.
Jocelyn H. Leu
From the University of Texas McGovern Medical School, Houston, Texas; Oregon Health & Science University, Portland, Oregon; Arizona Arthritis and Rheumatology Associates, Phoenix, Arizona; Janssen Research & Development LLC, Spring House, Pennsylvania; University of Pennsylvania, Philadelphia, Pennsylvania, USA; AMED Medical Center, Warsaw, Poland. This study was funded by Janssen Research & Development LLC, which manufactures golimumab. Drs. Caldron and Dudek served as trial investigators for Janssen. Dr. Reveille has received consultancies from Eli Lilly, Janssen, Novartis, Pfizer, and UCB, has served as a trial investigator for Janssen and Eli Lilly, and has received a research grant from Janssen. Dr. Deodhar has received consultancies, speaking fees, and/or honoraria from Eli Lilly, Janssen, Novartis, Pfizer, and UCB. Drs. Harrison and Hsia, and L. Kim, K.H. Lo, and J.H. Leu are or were employees of Janssen Research & Development LLC at the time this work was performed, and own stock in Johnson & Johnson, of which Janssen Research & Development LLC is a wholly owned subsidiary. J.D. Reveille, MD, University of Texas McGovern Medical School; A. Deodhar, MD, Oregon Health & Science University; P.H. Caldron, DO, Arizona Arthritis and Rheumatology Associates; A. Dudek, MD, PhD, AMED Medical Center; D.D. Harrison, MD, MPH, Janssen Research & Development LLC; L. Kim, PhD, Janssen Research & Development LLC; K.H. Lo, PhD, Janssen Research & Development LLC; J.H. Leu, PharmD, PhD, Janssen Research & Development LLC; E.C. Hsia, MD, MSCE, Janssen Research & Development LLC, and University of Pennsylvania. Address correspondence to Dr. E.C. Hsia, Janssen Research & Development LLC, 1400 McKean Road, PO Box 776, Spring House, Pennsylvania 19477, USA. E-mail: ehsia@its.jnj.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication November 22, 2018.
Elizabeth C. Hsia
From the University of Texas McGovern Medical School, Houston, Texas; Oregon Health & Science University, Portland, Oregon; Arizona Arthritis and Rheumatology Associates, Phoenix, Arizona; Janssen Research & Development LLC, Spring House, Pennsylvania; University of Pennsylvania, Philadelphia, Pennsylvania, USA; AMED Medical Center, Warsaw, Poland. This study was funded by Janssen Research & Development LLC, which manufactures golimumab. Drs. Caldron and Dudek served as trial investigators for Janssen. Dr. Reveille has received consultancies from Eli Lilly, Janssen, Novartis, Pfizer, and UCB, has served as a trial investigator for Janssen and Eli Lilly, and has received a research grant from Janssen. Dr. Deodhar has received consultancies, speaking fees, and/or honoraria from Eli Lilly, Janssen, Novartis, Pfizer, and UCB. Drs. Harrison and Hsia, and L. Kim, K.H. Lo, and J.H. Leu are or were employees of Janssen Research & Development LLC at the time this work was performed, and own stock in Johnson & Johnson, of which Janssen Research & Development LLC is a wholly owned subsidiary. J.D. Reveille, MD, University of Texas McGovern Medical School; A. Deodhar, MD, Oregon Health & Science University; P.H. Caldron, DO, Arizona Arthritis and Rheumatology Associates; A. Dudek, MD, PhD, AMED Medical Center; D.D. Harrison, MD, MPH, Janssen Research & Development LLC; L. Kim, PhD, Janssen Research & Development LLC; K.H. Lo, PhD, Janssen Research & Development LLC; J.H. Leu, PharmD, PhD, Janssen Research & Development LLC; E.C. Hsia, MD, MSCE, Janssen Research & Development LLC, and University of Pennsylvania. Address correspondence to Dr. E.C. Hsia, Janssen Research & Development LLC, 1400 McKean Road, PO Box 776, Spring House, Pennsylvania 19477, USA. E-mail: ehsia@its.jnj.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication November 22, 2018.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study
John D. Reveille, Atul Deodhar, Paul H. Caldron, Anna Dudek, Diane D. Harrison, Lilianne Kim, Kim Hung Lo, Jocelyn H. Leu, Elizabeth C. Hsia
The Journal of Rheumatology Mar 2019, jrheum.180718; DOI: 10.3899/jrheum.180718
Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study
John D. Reveille, Atul Deodhar, Paul H. Caldron, Anna Dudek, Diane D. Harrison, Lilianne Kim, Kim Hung Lo, Jocelyn H. Leu, Elizabeth C. Hsia
The Journal of Rheumatology Mar 2019, jrheum.180718; DOI: 10.3899/jrheum.180718